Avanos Medical's 15min Chart Indicates MACD Death Cross and Bearish Marubozu

Avanos Medical's 15-minute chart has recently exhibited a significant technical indicator, the MACD Death Cross, accompanied by a Bearish Marubozu at 08/12/2025 13:45. This suggests that the stock price may continue to decline, with sellers dominating the market and bearish momentum likely to persist.

Avanos Medical Inc. (AVNS) has recently encountered significant technical challenges, as evidenced by the appearance of a MACD Death Cross and a Bearish Marubozu on its 15-minute chart on August 12, 2025, at 13:45. This development suggests that the stock price may continue to decline, with sellers dominating the market and bearish momentum likely to persist.

The MACD Death Cross and KDJ Death Cross signals, as reported on August 7, 2025, at 16:00, indicated a potential continuation of the downward trend in Avanos Medical's stock price. These technical indicators suggest a shift in momentum towards a negative direction, potentially leading to further declines [1].

In the second quarter of 2025, Avanos Medical reported mixed financial results. The company's adjusted earnings per share (EPS) from continuing operations were 17 cents, down 50% year over year, and missed the Zacks Consensus Estimate by 5.6%. Gross revenue for the quarter was $175 million, up 1.9% year over year, and exceeded the Zacks Consensus Estimate by 4.7% [1]. The company's strong performance in the Specialty Nutrition Systems (SNS) portfolio and radiofrequency ablation (RFA) generator sales partially offset the lower volume in its surgical pain and recovery portfolio. However, the company faced challenges in the Pain Management and Recovery (PM&R) segment, where revenues declined by 2.9% year over year, and the surgical pain and recovery unit experienced a 9.4% year-over-year decline [1].

The company's cash position remained relatively stable, with cash and cash equivalents at $90.3 million at the end of the second quarter, compared to $97 million at the first-quarter end. Total debt also decreased slightly to $105.1 million from $107.4 million. Despite these financial results, Avanos Medical continues to face a volatile tariff environment, with estimated incremental manufacturing costs of approximately $15 million for the year [1].

The MACD and KDJ Death Cross signals a potential continuation of the downward trend in Avanos Medical's stock price, driven by the company's ongoing challenges in specific segments and the broader impact of tariffs. Investors should closely monitor the company's financial performance and strategic initiatives to mitigate these challenges.

References:
[1] https://www.nasdaq.com/articles/avanos-medical-stock-down-q2-earnings-miss-estimates-margins-down
[2] https://www.marketbeat.com/stocks/NYSE/AVNS/